Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common antidepressant plus a special diet tame IBS diarrhea?

NCT ID NCT06684470

Symptom relief Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study at Mayo Clinic tests whether adding the medication mirtazapine to a low-FODMAP diet improves symptoms of irritable bowel syndrome with diarrhea (IBS-D) better than diet alone. About 20 adults aged 18-70 will take either mirtazapine or a placebo while following the diet. The goal is to see if the combo reduces abdominal pain, bloating, and diarrhea.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mirtazapine (a neuromodulator) and a low-FODMAP diet
What this could lead to
If it works, this could point toward a more effective way to manage IBS with diarrhea by combining diet changes with medication.
What could go wrong
This is a very early, small pilot study with only 20 people. Results may not apply to everyone, and mirtazapine can cause side effects like drowsiness and weight gain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must meet all of the inclusion criteria to participate in this study: * Adults (ages 18-70) * Score of \>175 on the IBS-SSS questionnaire * Must meet Rome IV criteria for IBS-D * If subject is of reproductive capability a negative urine pregnancy test must be available prior to entering the study * Ability to understand study procedures and to comply with them for the entire length of the study Exclusion Criteria: * All candidates meeting any of the below exclusion criteria at baseline will be excluded from study participation: * Score of \< 175 on the IBS-SSS * Prior diagnoses of: known celiac disease, small intestinal bacterial overgrowth, inflammatory bowel disease, or microscopic colitis * Ongoing significant anxiety or depression * A history of a known side effect to mirtazapine * Prior treatment with a low FODMAP diet or mirtazapine without clinical benefit * Active alcohol or drug abuse * Inability to read or understand the consent form * Any other medical or psychological reason that would prevent active participation in a research study * Pregnant females

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diarrhea are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diarrheal disease irritable bowel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diarrhea IBS - irritable bowel syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mayo Clinic

    RECRUITING

    Jacksonville, Florida, 32224, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.